{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T20:40:07Z","timestamp":1756500007802,"version":"3.44.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13346-025-01831-x","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T11:07:56Z","timestamp":1741432076000},"page":"3737-3752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Local delivery of an adenosine receptor agonist reduces inflammation associated with contact hypersensitivity"],"prefix":"10.1007","volume":"15","author":[{"given":"Elizabeth R.","family":"Bentley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacia","family":"Subick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Doran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Kobyra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Balmert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-3931","authenticated-orcid":false,"given":"Steven R.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"1831_CR1","doi-asserted-by":"publisher","unstructured":"Martin SF, Rustemeyer T, Thyssen JP. Recent advances in understanding and managing contact dermatitis. F1000Res. 2018;7. https:\/\/doi.org\/10.12688\/f1000research.13499.1.","DOI":"10.12688\/f1000research.13499.1"},{"key":"1831_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jconrel.2017.07.006","volume":"261","author":"SC Balmert","year":"2017","unstructured":"Balmert SC, Donahue C, Vu JR, Erdos G, Falo LD Jr, Little SR. In vivo induction of regulatory T cells promotes allergen tolerance and suppresses allergic contact dermatitis. J Control Release. 2017;261:223\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.006.","journal-title":"J Control Release"},{"key":"1831_CR3","doi-asserted-by":"publisher","first-page":"105282","DOI":"10.1016\/j.phrs.2020.105282","volume":"162","author":"GS Brites","year":"2020","unstructured":"Brites GS, Ferreira I, Sebastiao AI, Silva A, Carrascal M, Neves BM, et al. Allergic contact dermatitis: From pathophysiology to development of new preventive strategies. Pharmacol Res. 2020;162:105282. https:\/\/doi.org\/10.1016\/j.phrs.2020.105282.","journal-title":"Pharmacol Res"},{"issue":"5","key":"1831_CR4","first-page":"284","volume":"14","author":"P Saint-Mezard","year":"2004","unstructured":"Saint-Mezard P, Rosieres A, Krasteva M, Berard F, Dubois B, Kaiserlian D, et al. Allergic contact dermatitis. Eur J Dermatol. 2004;14(5):284\u201395.","journal-title":"Eur J Dermatol"},{"key":"1831_CR5","doi-asserted-by":"publisher","first-page":"1184289","DOI":"10.3389\/fmed.2023.1184289","volume":"10","author":"M Tramontana","year":"2023","unstructured":"Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L. Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches. Front Med (Lausanne). 2023;10:1184289. https:\/\/doi.org\/10.3389\/fmed.2023.1184289.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1831_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nri3150","volume":"12","author":"DH Kaplan","year":"2012","unstructured":"Kaplan DH, Igyarto BZ, Gaspari AA. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol. 2012;12(2):114\u201324. https:\/\/doi.org\/10.1038\/nri3150.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1831_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4103\/2229-5178.142483","volume":"5","author":"A Coondoo","year":"2014","unstructured":"Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416\u201325. https:\/\/doi.org\/10.4103\/2229-5178.142483.","journal-title":"Indian Dermatol Online J"},{"key":"1831_CR8","doi-asserted-by":"publisher","first-page":"113971","DOI":"10.1016\/j.addr.2021.113971","volume":"178","author":"ER Bentley","year":"2021","unstructured":"Bentley ER, Little SR. Local delivery strategies to restore immune homeostasis in the context of inflammation. Adv Drug Deliv Rev. 2021;178:113971. https:\/\/doi.org\/10.1016\/j.addr.2021.113971.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"1831_CR9","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1084\/jem.20092489","volume":"207","author":"FC Weber","year":"2010","unstructured":"Weber FC, Esser PR, Muller T, Ganesan J, Pellegatti P, Simon MM, et al. Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J Exp Med. 2010;207(12):2609\u201319. https:\/\/doi.org\/10.1084\/jem.20092489.","journal-title":"J Exp Med"},{"key":"1831_CR10","doi-asserted-by":"publisher","unstructured":"Sebastiao AI, Ferreira I, Brites G, Silva A, Neves BM, Teresa Cruz M. NLRP3 Inflammasome and Allergic Contact Dermatitis: A Connection to Demystify. Pharmaceutics. 2020;12(9). https:\/\/doi.org\/10.3390\/pharmaceutics12090867.","DOI":"10.3390\/pharmaceutics12090867"},{"key":"1831_CR11","doi-asserted-by":"publisher","unstructured":"Chen L, Lei X, Mahnke K. Adenosine and its receptors in the pathogenesis and treatment of inflammatory skin diseases. Int J Mol Sci. 2024;25(11). https:\/\/doi.org\/10.3390\/ijms25115810.","DOI":"10.3390\/ijms25115810"},{"key":"1831_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.mam.2017.01.002","volume":"55","author":"MM Faas","year":"2017","unstructured":"Faas MM, Saez T, de Vos P. Extracellular ATP and adenosine: The Yin and Yang in immune responses? Mol Aspects Med. 2017;55:9\u201319. https:\/\/doi.org\/10.1016\/j.mam.2017.01.002.","journal-title":"Mol Aspects Med"},{"key":"1831_CR13","doi-asserted-by":"publisher","unstructured":"Effendi WI, Nagano T, Kobayashi K, Nishimura Y. Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells. 2020;9(3). https:\/\/doi.org\/10.3390\/cells9030785.","DOI":"10.3390\/cells9030785"},{"key":"1831_CR14","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3389\/fimmu.2018.02581","volume":"9","author":"C Silva-Vilches","year":"2018","unstructured":"Silva-Vilches C, Ring S, Mahnke K. ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity. Front Immunol. 2018;9:2581. https:\/\/doi.org\/10.3389\/fimmu.2018.02581.","journal-title":"Front Immunol"},{"key":"1831_CR15","doi-asserted-by":"publisher","unstructured":"Fishman P. Drugs targeting the A3 adenosine receptor: Human clinical study data. Molecules. 2022;27(12). https:\/\/doi.org\/10.3390\/molecules27123680.","DOI":"10.3390\/molecules27123680"},{"issue":"10","key":"1831_CR16","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","volume":"61","author":"DA Smith","year":"2018","unstructured":"Smith DA, Beaumont K, Maurer TS, Di L. Relevance of half-life in drug design. J Med Chem. 2018;61(10):4273\u201382. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00969.","journal-title":"J Med Chem"},{"issue":"6","key":"1831_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/jdv.19811","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp KA, Beyska-Rizova S, Gantcheva ML, Slavcheva Simeonova E, Brezoev P, Celic M, et al. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). J Eur Acad Dermatol Venereol. 2024;38(6):1112\u201320. https:\/\/doi.org\/10.1111\/jdv.19811.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1831_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","volume":"26","author":"M David","year":"2012","unstructured":"David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012;26(3):361\u20137. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04078.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1831_CR19","first-page":"931","volume":"15","author":"M David","year":"2016","unstructured":"David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, et al. Treatment of plaque-type psoriasis with Oral CF101: Data from a Phase II\/III multicenter, randomized controlled trial. J Drugs Dermatol. 2016;15(8):931\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1831_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0169-409x(97)00049-5","volume":"28","author":"JW McGinity","year":"1997","unstructured":"McGinity JW, O\u2019Donnell PB. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev. 1997;28(1):25\u201342. https:\/\/doi.org\/10.1016\/s0169-409x(97)00049-5.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1831_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2012.01.013","volume":"159","author":"S Jhunjhunwala","year":"2012","unstructured":"Jhunjhunwala S, Balmert SC, Raimondi G, Dons E, Nichols EE, Thomson AW, et al. Controlled release formulations of IL-2, TGF-beta1 and rapamycin for the induction of regulatory T cells. J Control Release. 2012;159(1):78\u201384. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.013.","journal-title":"J Control Release"},{"issue":"3","key":"1831_CR22","doi-asserted-by":"publisher","first-page":"151906","DOI":"10.1016\/j.imbio.2020.151906","volume":"225","author":"SH Huang","year":"2020","unstructured":"Huang SH, Wu CH, Chen SJ, Sytwu HK, Lin GJ. Immunomodulatory effects and potential clinical applications of dimethyl sulfoxide. Immunobiology. 2020;225(3):151906. https:\/\/doi.org\/10.1016\/j.imbio.2020.151906.","journal-title":"Immunobiology"},{"issue":"2","key":"1831_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.immuni.2012.07.011","volume":"37","author":"MY Gerner","year":"2012","unstructured":"Gerner MY, Kastenmuller W, Ifrim I, Kabat J, Germain RN. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. Immunity. 2012;37(2):364\u201376. https:\/\/doi.org\/10.1016\/j.immuni.2012.07.011.","journal-title":"Immunity"},{"key":"1831_CR24","doi-asserted-by":"publisher","unstructured":"Mani V, Bromley SK, Aijo T, Mora-Buch R, Carrizosa E, Warner RD, et al. Migratory DCs activate TGF-beta to precondition naive CD8(+) T cells for tissue-resident memory fate. Science. 2019;366(6462). https:\/\/doi.org\/10.1126\/science.aav5728.","DOI":"10.1126\/science.aav5728"},{"issue":"2","key":"1831_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","volume":"19","author":"SC Eisenbarth","year":"2019","unstructured":"Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 2019;19(2):89\u2013103. https:\/\/doi.org\/10.1038\/s41577-018-0088-1.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1831_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","volume":"22","author":"JM Curtsinger","year":"2010","unstructured":"Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22(3):333\u201340. https:\/\/doi.org\/10.1016\/j.coi.2010.02.013.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"1831_CR27","doi-asserted-by":"publisher","first-page":"10458","DOI":"10.1016\/j.jbc.2023.104587","volume":"299","author":"K Furuta","year":"2023","unstructured":"Furuta K, Onishi H, Ikada Y, Masaki K, Tanaka S, Kaito C. ATP and its metabolite adenosine cooperatively upregulate the antigen-presenting molecules on dendritic cells leading to IFN-gamma production by T cells. J Biol Chem. 2023;299(4):10458. https:\/\/doi.org\/10.1016\/j.jbc.2023.104587.","journal-title":"J Biol Chem"},{"key":"1831_CR28","doi-asserted-by":"publisher","unstructured":"Alam MS, Otsuka S, Wong N, Abbasi A, Gaida MM, Fan Y, et al. TNF plays a crucial role in inflammation by signaling via T cell TNFR2. Proc Natl Acad Sci U S A. 2021;118(50). https:\/\/doi.org\/10.1073\/pnas.2109972118.","DOI":"10.1073\/pnas.2109972118"},{"issue":"1","key":"1831_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40425-018-0494-8","volume":"7","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen J, Bi E, Zhao Y, Qin T, Wang Y, et al. TNF-alpha enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways. J Immunother Cancer. 2019;7(1):28. https:\/\/doi.org\/10.1186\/s40425-018-0494-8.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1831_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri2526","volume":"9","author":"M Croft","year":"2009","unstructured":"Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271\u201385. https:\/\/doi.org\/10.1038\/nri2526.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1831_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1124\/jpet.105.096016","volume":"317","author":"LM Kreckler","year":"2006","unstructured":"Kreckler LM, Wan TC, Ge ZD, Auchampach JA. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006;317(1):172\u201380. https:\/\/doi.org\/10.1124\/jpet.105.096016.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2\u20133","key":"1831_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0014-2999(96)00272-5","volume":"310","author":"CD McWhinney","year":"1996","unstructured":"McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol. 1996;310(2\u20133):209\u201316. https:\/\/doi.org\/10.1016\/0014-2999(96)00272-5.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1831_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2005.11.004","volume":"396","author":"JY Lee","year":"2006","unstructured":"Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, et al. Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase\/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett. 2006;396(1):1\u20136. https:\/\/doi.org\/10.1016\/j.neulet.2005.11.004.","journal-title":"Neurosci Lett"},{"key":"1831_CR34","doi-asserted-by":"publisher","first-page":"818251","DOI":"10.1155\/2014\/818251","volume":"2014","author":"T Ren","year":"2014","unstructured":"Ren T, Qiu Y, Wu W, Feng X, Ye S, Wang Z, et al. Activation of adenosine A3 receptor alleviates TNF-alpha-induced inflammation through inhibition of the NF-kappaB signaling pathway in human colonic epithelial cells. Mediators Inflamm. 2014;2014:818251. https:\/\/doi.org\/10.1155\/2014\/818251.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"1831_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clim.2015.04.013","volume":"160","author":"JD Fisher","year":"2015","unstructured":"Fisher JD, Acharya AP, Little SR. Micro and nanoparticle drug delivery systems for preventing allotransplant rejection. Clin Immunol. 2015;160(1):24\u201335. https:\/\/doi.org\/10.1016\/j.clim.2015.04.013.","journal-title":"Clin Immunol"},{"issue":"28","key":"1831_CR36","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1002\/adma.201200224","volume":"24","author":"SC Balmert","year":"2012","unstructured":"Balmert SC, Little SR. Biomimetic delivery with micro- and nanoparticles. Adv Mater. 2012;24(28):3757\u201378. https:\/\/doi.org\/10.1002\/adma.201200224.","journal-title":"Adv Mater"},{"issue":"4","key":"1831_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40204-020-00139-y","volume":"9","author":"E Lagreca","year":"2020","unstructured":"Lagreca E, Onesto V, Di Natale C, La Manna S, Netti PA, Vecchione R. Recent advances in the formulation of PLGA microparticles for controlled drug delivery. Prog Biomater. 2020;9(4):153\u201374. https:\/\/doi.org\/10.1007\/s40204-020-00139-y.","journal-title":"Prog Biomater"},{"key":"1831_CR38","doi-asserted-by":"publisher","first-page":"112729","DOI":"10.1016\/j.intimp.2024.112729","volume":"140","author":"X Zeng","year":"2024","unstructured":"Zeng X, Hu Y, Qiao S, Cao X, Dai Y, Wu F, et al. ADORA3 activation promotes goblet cell differentiation via enhancing HMGCS2-mediated ketogenesis in ulcerative colitis. Int Immunopharmacol. 2024;140:112729. https:\/\/doi.org\/10.1016\/j.intimp.2024.112729.","journal-title":"Int Immunopharmacol"},{"key":"1831_CR39","doi-asserted-by":"publisher","unstructured":"Bentley ER, Subick S, Pezzillo M, Balmert SC, Herbert A, Little SR. Identification and characterization of critical processing parameters in the fabrication of double-emulsion poly(lactic-co-glycolic) acid microparticles. Pharmaceutics. 2024;16(6). https:\/\/doi.org\/10.3390\/pharmaceutics16060796.","DOI":"10.3390\/pharmaceutics16060796"},{"key":"1831_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.actbio.2018.03.002","volume":"71","author":"ML Ratay","year":"2018","unstructured":"Ratay ML, Balmert SC, Bassin EJ, Little SR. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease. Acta Biomater. 2018;71:261\u201370. https:\/\/doi.org\/10.1016\/j.actbio.2018.03.002.","journal-title":"Acta Biomater"},{"key":"1831_CR41","doi-asserted-by":"publisher","unstructured":"Yonet-Tanyeri N, Parker RS, Falo LD, Jr., Little SR. Investigation of the impact of manufacturing methods on protein-based long-acting injectable formulations: A comparative assessment for microfluidics vs. conventional methods. Pharmaceutics. 2024;16(10). https:\/\/doi.org\/10.3390\/pharmaceutics16101264.","DOI":"10.3390\/pharmaceutics16101264"},{"issue":"4","key":"1831_CR42","doi-asserted-by":"publisher","first-page":"103936","DOI":"10.1016\/j.drudis.2024.103936","volume":"29","author":"SE Alavi","year":"2024","unstructured":"Alavi SE, Alharthi S, Alavi SF, Alavi SZ, Zahra GE, Raza A, et al. Microfluidics for personalized drug delivery. Drug Discov Today. 2024;29(4):103936. https:\/\/doi.org\/10.1016\/j.drudis.2024.103936.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1831_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02980037","volume":"27","author":"Y Yeo","year":"2004","unstructured":"Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res. 2004;27(1):1\u201312. https:\/\/doi.org\/10.1007\/BF02980037.","journal-title":"Arch Pharm Res"},{"key":"1831_CR44","doi-asserted-by":"publisher","unstructured":"Zielinska A, Carreiro F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16). https:\/\/doi.org\/10.3390\/molecules25163731.","DOI":"10.3390\/molecules25163731"},{"issue":"1","key":"1831_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00411-013-0500-y","volume":"53","author":"M Hofer","year":"2014","unstructured":"Hofer M, Pospisil M, Dusek L, Hoferova Z, Komurkova D. Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of gamma-irradiated mice. Radiat Environ Biophys. 2014;53(1):211\u20135. https:\/\/doi.org\/10.1007\/s00411-013-0500-y.","journal-title":"Radiat Environ Biophys"},{"issue":"4","key":"1831_CR46","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","volume":"15","author":"AM Fathallah","year":"2013","unstructured":"Fathallah AM, Bankert RB, Balu-Iyer SV. Immunogenicity of subcutaneously administered therapeutic proteins\u2013a mechanistic perspective. AAPS J. 2013;15(4):897\u2013900. https:\/\/doi.org\/10.1208\/s12248-013-9510-6.","journal-title":"AAPS J"},{"issue":"2","key":"1831_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1046\/j.1365-2567.1999.00850.x","volume":"98","author":"MB Lappin","year":"1999","unstructured":"Lappin MB, Weiss JM, Delattre V, Mai B, Dittmar H, Maier C, et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology. 1999;98(2):181\u20138. https:\/\/doi.org\/10.1046\/j.1365-2567.1999.00850.x.","journal-title":"Immunology"},{"issue":"12","key":"1831_CR48","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/j.1398-9995.2009.02082.x","volume":"64","author":"M Vocanson","year":"2009","unstructured":"Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy. 2009;64(12):1699\u2013714. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02082.x.","journal-title":"Allergy"},{"key":"1831_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 Agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47\u201358. https:\/\/doi.org\/10.1146\/annurev-med-062518-045435.","journal-title":"Annu Rev Med"},{"key":"1831_CR50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","volume":"141","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2019;141:92\u2013103. https:\/\/doi.org\/10.1016\/j.addr.2018.12.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"1831_CR51","doi-asserted-by":"publisher","first-page":"861471","DOI":"10.3389\/fimmu.2022.861471","volume":"13","author":"S Perrin","year":"2022","unstructured":"Perrin S, Magill M. The inhibition of CD40\/CD154 costimulatory signaling in the prevention of renal transplant rejection in nonhuman primates: A systematic review and meta analysis. Front Immunol. 2022;13:861471. https:\/\/doi.org\/10.3389\/fimmu.2022.861471.","journal-title":"Front Immunol"},{"issue":"1","key":"1831_CR52","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-6143.2011.03736.x","volume":"12","author":"IR Badell","year":"2012","unstructured":"Badell IR, Thompson PW, Turner AP, Russell MC, Avila JG, Cano JA, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant. 2012;12(1):126\u201335. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03736.x.","journal-title":"Am J Transplant"},{"issue":"7","key":"1831_CR53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","volume":"390","author":"P Vermersch","year":"2024","unstructured":"Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, et al. Inhibition of CD40L with Frexalimab in multiple sclerosis. N Engl J Med. 2024;390(7):589\u2013600. https:\/\/doi.org\/10.1056\/NEJMoa2309439.","journal-title":"N Engl J Med"},{"key":"1831_CR54","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fimmu.2013.00438","volume":"4","author":"AM Dudek","year":"2013","unstructured":"Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semi-mature, and fully mature dendritic cells: Toward a DC-Cancer cells interface that augments anticancer immunity. Front Immunol. 2013;4:438. https:\/\/doi.org\/10.3389\/fimmu.2013.00438.","journal-title":"Front Immunol"},{"key":"1831_CR55","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fimmu.2012.00274","volume":"3","author":"SV Schmidt","year":"2012","unstructured":"Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012;3:274. https:\/\/doi.org\/10.3389\/fimmu.2012.00274.","journal-title":"Front Immunol"},{"issue":"6","key":"1831_CR56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/13543784.2011.573785","volume":"20","author":"B Koscso","year":"2011","unstructured":"Koscso B, Csoka B, Pacher P, Hasko G. Investigational A(3) adenosine receptor targeting agents. Expert Opin Investig Drugs. 2011;20(6):757\u201368. https:\/\/doi.org\/10.1517\/13543784.2011.573785.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"1831_CR57","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/sj.jid.5700174","volume":"126","author":"M Vocanson","year":"2006","unstructured":"Vocanson M, Hennino A, Cluzel-Tailhardat M, Saint-Mezard P, Benetiere J, Chavagnac C, et al. CD8+ T cells are effector cells of contact dermatitis to common skin allergens in mice. J Invest Dermatol. 2006;126(4):815\u201320. https:\/\/doi.org\/10.1038\/sj.jid.5700174.","journal-title":"J Invest Dermatol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01831-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01831-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01831-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T20:23:34Z","timestamp":1756499014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01831-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1831"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01831-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"type":"print","value":"2190-393X"},{"type":"electronic","value":"2190-3948"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"26 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed, including a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pittsburgh.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}